Tags

Type your tag names separated by a space and hit enter

Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage.
Crit Care Med. 1999 May; 27(5):965-71.CC

Abstract

OBJECTIVE

To determine the effect of mean arterial pressure (MAP) reduction on regional cerebral blood flow and intracranial pressure (ICP) in intracerebral hemorrhage. We tested the hypothesis that there is ischemia in the perihematoma region after intracerebral hemorrhage, which can be exacerbated by a pharmacologic reduction of MAP.

DESIGN

Prospective, controlled, laboratory trial.

SETTING

Animal research laboratory.

SUBJECTS

Eighteen mongrel dogs, weighing 15 to 25 kg.

INTERVENTIONS

We introduced intracerebral hemorrhage in 12 anesthetized dogs by autologous blood injection under arterial pressure in the deep white matter adjacent to the left caudate region. We measured serial regional cerebral blood flow using radiolabeled microspheres in animals with two different volumes of injected blood (2.8 mL [Group A, n = 6] and 4.4 mL [Group B, n = 6]) and compared them with control animals (n = 6). Intravenous labetalol was administered 90 mins after administration of hematoma, while maintaining cerebral perfusion pressure >65 mm Hg. Regional cerebral blood flow measurements were repeated 10 and 30 mins after labetalol administration. MAP and ICP were monitored continuously using intra-arterial and cisterna magna catheters, respectively.

MEASUREMENTS AND MAIN RESULTS

Compared with control animals, significant elevation in ICP was observed in Groups A and B and elevation in MAP was observed in Group B at 45 mins after injection of blood. These hemodynamic alterations were not accompanied by any significant differences in regional cerebral blood flow in any group. Administration of labetalol resulted in a decrease in MAP (mm Hg+/-SEM) in Groups A (119.0+/-9.2 to 103.0+/-9.1) and B (124.5+/-7.4 to 100.5+/-4.8) and controls (103.5+/-4.3 to 85.0+/-8.0). No differences were observed in regional cerebral blood flow after MAP reduction in both Groups A and B compared with controls in regions around or distant to the hematoma. There were no changes in ICP in Groups A and B both at 10 and 30 mins after reduction in MAP compared with pretreatment values.

CONCLUSIONS

In our model, pharmacologic reduction of MAP within the normal autoregulatory limits of cerebral perfusion pressure, 90 mins after onset, had no adverse effect on ICP and regional cerebral blood flow in regions around or distant to the hematoma. These results support the controlled use of antihypertensive treatment in intracerebral hemorrhage in the initial time period.

Links

Aggregator Full Text

Authors+Show Affiliations

Qureshi AI
Division of Neurosciences Critical Care, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Wilson DA
No affiliation info available
Hanley DF
No affiliation info available
Traystman RJ
No affiliation info available

MeSH

AnimalsAntihypertensive AgentsBlood Flow VelocityBlood PressureBrain IschemiaCerebral HemorrhageCerebrovascular CirculationDisease Models, AnimalDogsDrug Evaluation, PreclinicalDrug MonitoringFemaleInfusions, IntravenousIntracranial PressureLabetalolMaleProspective StudiesTime FactorsVascular Resistance

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10362421

Citation

Qureshi, A I., et al. "Pharmacologic Reduction of Mean Arterial Pressure Does Not Adversely Affect Regional Cerebral Blood Flow and Intracranial Pressure in Experimental Intracerebral Hemorrhage." Critical Care Medicine, vol. 27, no. 5, 1999, pp. 965-71.
Qureshi AI, Wilson DA, Hanley DF, et al. Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage. Crit Care Med. 1999;27(5):965-71.
Qureshi, A. I., Wilson, D. A., Hanley, D. F., & Traystman, R. J. (1999). Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage. Critical Care Medicine, 27(5), 965-71.
Qureshi AI, et al. Pharmacologic Reduction of Mean Arterial Pressure Does Not Adversely Affect Regional Cerebral Blood Flow and Intracranial Pressure in Experimental Intracerebral Hemorrhage. Crit Care Med. 1999;27(5):965-71. PubMed PMID: 10362421.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage. AU - Qureshi,A I, AU - Wilson,D A, AU - Hanley,D F, AU - Traystman,R J, PY - 1999/6/11/pubmed PY - 1999/6/11/medline PY - 1999/6/11/entrez SP - 965 EP - 71 JF - Critical care medicine JO - Crit Care Med VL - 27 IS - 5 N2 - OBJECTIVE: To determine the effect of mean arterial pressure (MAP) reduction on regional cerebral blood flow and intracranial pressure (ICP) in intracerebral hemorrhage. We tested the hypothesis that there is ischemia in the perihematoma region after intracerebral hemorrhage, which can be exacerbated by a pharmacologic reduction of MAP. DESIGN: Prospective, controlled, laboratory trial. SETTING: Animal research laboratory. SUBJECTS: Eighteen mongrel dogs, weighing 15 to 25 kg. INTERVENTIONS: We introduced intracerebral hemorrhage in 12 anesthetized dogs by autologous blood injection under arterial pressure in the deep white matter adjacent to the left caudate region. We measured serial regional cerebral blood flow using radiolabeled microspheres in animals with two different volumes of injected blood (2.8 mL [Group A, n = 6] and 4.4 mL [Group B, n = 6]) and compared them with control animals (n = 6). Intravenous labetalol was administered 90 mins after administration of hematoma, while maintaining cerebral perfusion pressure >65 mm Hg. Regional cerebral blood flow measurements were repeated 10 and 30 mins after labetalol administration. MAP and ICP were monitored continuously using intra-arterial and cisterna magna catheters, respectively. MEASUREMENTS AND MAIN RESULTS: Compared with control animals, significant elevation in ICP was observed in Groups A and B and elevation in MAP was observed in Group B at 45 mins after injection of blood. These hemodynamic alterations were not accompanied by any significant differences in regional cerebral blood flow in any group. Administration of labetalol resulted in a decrease in MAP (mm Hg+/-SEM) in Groups A (119.0+/-9.2 to 103.0+/-9.1) and B (124.5+/-7.4 to 100.5+/-4.8) and controls (103.5+/-4.3 to 85.0+/-8.0). No differences were observed in regional cerebral blood flow after MAP reduction in both Groups A and B compared with controls in regions around or distant to the hematoma. There were no changes in ICP in Groups A and B both at 10 and 30 mins after reduction in MAP compared with pretreatment values. CONCLUSIONS: In our model, pharmacologic reduction of MAP within the normal autoregulatory limits of cerebral perfusion pressure, 90 mins after onset, had no adverse effect on ICP and regional cerebral blood flow in regions around or distant to the hematoma. These results support the controlled use of antihypertensive treatment in intracerebral hemorrhage in the initial time period. SN - 0090-3493 UR - https://www.unboundmedicine.com/medline/citation/10362421/Pharmacologic_reduction_of_mean_arterial_pressure_does_not_adversely_affect_regional_cerebral_blood_flow_and_intracranial_pressure_in_experimental_intracerebral_hemorrhage_ L2 - https://dx.doi.org/10.1097/00003246-199905000-00036 DB - PRIME DP - Unbound Medicine ER -